Cardiopulmonary Autotransfusion System is a sophisticated device with an exceptionally effective design that provides autologous blood during surgical procedures.
Autotransfusion is a process wherein a person receives their own blood for a transfusion, instead of banked allogenic (separate-donor) blood. There are two main kinds of Autotransfusion: Blood can be autologous "pre-donated" (termed so despite "donation" not typically referring to giving to one's self) before a surgery, or alternatively, it can be collected during and after the surgery using an intraoperative blood salvage device. The latter form of Autotransfusion is utilized in surgeries where there is expected a large volume blood loss.
Scope of the Report:
The rising prevalence of cardiovascular diseases (CVDs), advancements in technology, and increasing investments in R&D are some of the factors that will propel growth in the cardiopulmonary Autotransfusion systems market in the Americas during the forecast period.
Table of Contents
1 Market Overview
1.1 Cardiopulmonary Autotransfusion System Introduction
1.2 Market Analysis by Type
1.2.1 Unwashed ATS
1.2.2 Washed ATS
1.3 Market Analysis by Applications
1.3.1 Heart Surgery
1.3.2 Great Organ Transplant Surgery
1.3.3 Other Surgery
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
18.104.22.168 United States Market States and Outlook (2014-2024)
22.214.171.124 Canada Market States and Outlook (2014-2024)
126.96.36.199 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
188.8.131.52 Germany Market States and Outlook (2014-2024)
184.108.40.206 France Market States and Outlook (2014-2024)
220.127.116.11 UK Market States and Outlook (2014-2024)
18.104.22.168 Russia Market States and Outlook (2014-2024)
22.214.171.124 Italy Market States and Outlook (2014-20 ...